- Acadia Pharmaceuticals (ACAD -17.9%) shares are down sharply, with no recent news or information to account for the move, though biotech blogger Adam Feuerstein tweets a rumor that today's decline is due to a doctor on a Cowen panel having a bearish stance on its lead drug candidate pimavanserin.
- Pimavanserin is in Phase 3 development as a potential first-in-class treatment for Parkinson's disease psychosis, and ACAD established an expedited path to an NDA filing in Q2.
- Shares are up 403% YTD.
From other sites
at Nasdaq.com (Mar 27, 2015)
at 4-traders.com (Mar 23, 2015)
at Zacks.com (Mar 13, 2015)
at MarketWatch.com (Mar 11, 2015)
at CNBC.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs